Rachel C Jankowitz
Overview
Explore the profile of Rachel C Jankowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1992
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Blohmer M, Zhu L, Atkinson J, Beriwal S, Rodriguez-Lopez J, Rosenzweig M, et al.
Breast Cancer Res
. 2020 Jun;
22(1):70.
PMID: 32586354
Background: Breast cancer is the most common malignancy to spread to the orbit and periorbit, and the invasive lobular carcinoma (ILC) histologic subtype of breast cancer has been reported to...
22.
Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, et al.
Genet Epidemiol
. 2020 Mar;
44(5):442-468.
PMID: 32115800
Previous transcriptome-wide association studies (TWAS) have identified breast cancer risk genes by integrating data from expression quantitative loci and genome-wide association studies (GWAS), but analyses of breast cancer subtype-specific associations...
23.
Fachal L, Aschard H, Beesley J, Barnes D, Allen J, Kar S, et al.
Nat Genet
. 2020 Jan;
52(1):56-73.
PMID: 31911677
Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association analysis...
24.
Abraham J, Montero A, Jankowitz R, Salkeni M, Beumer J, Kiesel B, et al.
J Clin Oncol
. 2019 Aug;
37(29):2601-2609.
PMID: 31442103
Purpose: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab. Mechanisms of resistance have not been well...
25.
Cao L, Basudan A, Sikora M, Bahreini A, Tasdemir N, Levine K, et al.
Cancer Lett
. 2019 Jun;
461:21-30.
PMID: 31229512
Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer following invasive ductal carcinoma (IDC). To identify potential genetic drivers of ILC progression, we used NanoString...
26.
Friebel T, Andrulis I, Balmana J, Blanco A, Couch F, Daly M, et al.
Hum Mutat
. 2019 May;
40(10):1781-1796.
PMID: 31112363
BRCA1 and BRCA2 (BRCA1/2) pathogenic sequence variants (PSVs) confer elevated risks of multiple cancers. However, most BRCA1/2 PSVs reports focus on European ancestry individuals. Knowledge of the PSV distribution in...
27.
Ferreira M, Gamazon E, Al-Ejeh F, Aittomaki K, Andrulis I, Anton-Culver H, et al.
Nat Commun
. 2019 Apr;
10(1):1741.
PMID: 30988301
Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue and immune...
28.
Freedman R, Gelman R, Anders C, Melisko M, Parsons H, Cropp A, et al.
J Clin Oncol
. 2019 Mar;
37(13):1081-1089.
PMID: 30860945
Purpose: Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast...
29.
Han M, Salamat A, Zhu L, Zhang H, Clark B, Dabbs D, et al.
Mod Pathol
. 2019 Feb;
32(6):807-816.
PMID: 30723293
Metaplastic breast carcinoma is a rare heterogeneous category of breast cancer, often associated with a poor prognosis. Clinical-pathologic studies with respect to varied morphologic subtypes are lacking. There is also...
30.
Editorial: BRCA1 and BRCA2 gene mutations screening in sporadic breast cancer patients in Kazakhstan
Jankowitz R, Knickelbein K
Cent Asian J Glob Health
. 2018 May;
2(1):41.
PMID: 29755873
No abstract available.